BeiGene, Ltd. (ONC) reported $1.12 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 48.6%. EPS of $1.22 for the same period compares to -$2.41 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $1.12 billion, representing a surprise of -0.65%. The company delivered an EPS surprise of +271.83%, with the consensus EPS estimate being -$0.71.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how BeiGene performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Product revenue, net: $1.11 billion versus $1.12 billion estimated by four analysts on average.
- Product Revenue- BRUKINSA(Zanubrutinib): $791.66 million versus the four-analyst average estimate of $820.07 million.
- Product Revenue- Tislelizumab: $171.16 million versus $171.33 million estimated by four analysts on average.
- Product Revenue- XGEVA: $70.42 million versus the three-analyst average estimate of $56.55 million.
- Product Revenue- Other: $17.90 million compared to the $14.28 million average estimate based on three analysts.
- Product Revenue- POBEVCY: $13.75 million versus the three-analyst average estimate of $16.11 million.
- Product Revenue- BLINCYTO: $23.91 million versus $20.42 million estimated by three analysts on average.
- Product Revenue- KYPROLIS: $19.73 million versus the three-analyst average estimate of $16.51 million.
- Collaboration revenue: $8.75 million compared to the $6.49 million average estimate based on two analysts.
Shares of BeiGene have returned +15.4% over the past month versus the Zacks S&P 500 composite's +10.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>BeiGene, Ltd. (ONC) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
